|
|
| | RIPK1-IN-16 Basic information |
| Product Name: | RIPK1-IN-16 | | Synonyms: | RIPK1-IN-16;1H-1,2,4-Triazole-5-carboxamide, 3-(phenylmethyl)-N-[(3S)-2,3,4,5-tetrahydro-5-methyl-4-thioxo-1,5-benzoxazepin-3-yl]- | | CAS: | 2561431-77-2 | | MF: | C20H19N5O2S | | MW: | 393.46 | | EINECS: | | | Product Categories: | | | Mol File: | 2561431-77-2.mol |  |
| | RIPK1-IN-16 Chemical Properties |
| density | 1.424±0.10 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | pka | 8.740±0.40(predicted) |
| | RIPK1-IN-16 Usage And Synthesis |
| Uses | RIPK1-IN-16 is an orally active and potent inhibitor of RIPK1. RIPK1-IN-16 inhibits excessive inflammation by blocking RIPK1-mediated necroptosis in vivo. RIPK1-IN-16 protects mouse from TNF-induced systemic inflammatory response syndrome and sepsis[1]. | | References | [1] Ling ZY, et al. Protective Effect of a Novel RIPK1 Inhibitor, Compound 4-155, in Systemic Inflammatory Response Syndrome and Sepsis. Inflammation. 2023 Oct;46(5):1796-1809. DOI:10.1007/s10753-023-01842-1 |
| | RIPK1-IN-16 Preparation Products And Raw materials |
|